Survivin as a Preferential Target for Cancer Therapy
1
Department of Biochemistry & Molecular Biology, Faculty of Medicine, University of Calgary, 3330 Hospital Dr. NW., Calgary, AB T2N 4N1, Canada
2
Department of Pediatrics, Faculty of Medicine, University of Calgary, 3330 Hospital Dr. NW., Calgary, AB T2N 4N1, Canada
3
Department of Oncology, Faculty of Medicine, University of Calgary, 3330 Hospital Dr. NW., Calgary, AB T2N 4N1, Canada
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2014, 15(2), 2494-2516; https://doi.org/10.3390/ijms15022494
Received: 30 December 2013
/
Revised: 31 January 2014
/
Accepted: 7 February 2014
/
Published: 13 February 2014
(This article belongs to the Collection Programmed Cell Death and Apoptosis)
Cancer is typically a consequence of imbalance between cell death and proliferation in a way favorable to cell proliferation and survival. Most conventional cancer therapies are based on targeting rapidly growing cancerous cells to block growth or enhance cell death, thereby, restoring the balance between these processes. In many instances, malignancies that develop resistance to current treatment modalities, such as chemotherapy, immunotherapy, and radiotherapy often present the greatest challenge in subsequent management of the patient. Studies have shown that under normal circumstances, cells utilize different death mechanisms, such as apoptosis (programmed cell death), autophagy, mitotic catastrophe, and necrosis to maintain homeostasis and physiological integrity of the organism, but these processes often appear to be altered in cancer. Thus, in recent years developing various strategies for administration of cytotoxic chemotherapeutics in combination with apoptosis-sensitizing reagents is receiving more emphasis. Here, we review the properties of the anti-apoptotic protein, survivin, a member of the inhibitor of apoptosis protein (IAP) family and the clinical feasibility and anti-cancer potential of drugs targeting this protein. We also discuss some key points and concerns that should be taken into consideration while developing drugs that target apoptotic proteins, such as survivin.
View Full-Text
Keywords:
apoptosis; survivin; inhibitor of apoptosis (IAP); signaling; cancer therapy
▼
Show Figures
This is an open access article distributed under the Creative Commons Attribution License.
MDPI and ACS Style
Mobahat, M.; Narendran, A.; Riabowol, K. Survivin as a Preferential Target for Cancer Therapy. Int. J. Mol. Sci. 2014, 15, 2494-2516. https://doi.org/10.3390/ijms15022494
AMA Style
Mobahat M, Narendran A, Riabowol K. Survivin as a Preferential Target for Cancer Therapy. International Journal of Molecular Sciences. 2014; 15(2):2494-2516. https://doi.org/10.3390/ijms15022494
Chicago/Turabian StyleMobahat, Mahsa, Aru Narendran, and Karl Riabowol. 2014. "Survivin as a Preferential Target for Cancer Therapy" International Journal of Molecular Sciences 15, no. 2: 2494-2516. https://doi.org/10.3390/ijms15022494
Find Other Styles
